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Abstract Alzheimer’s disease is the fourth biggest killer
in developed countries. Amyloid precursor protein (APP)
plays a central role in the development of the disease,
through the generation of a peptide called A by proteoly-
sis of the precursor protein. APP can function as a metallo-
protein and modulate copper transport via its extracellular
copper binding domain (CuBD). Copper binding to this
domain has been shown to reduce A levels and hence a
molecular understanding of the interaction between metal
and protein could lead to the development of novel thera-
peutics to treat the disease. We have recently determined
the three-dimensional structures of apo and copper bound
forms of CuBD. The structures provide a mechanism by
which CuBD could readily transfer copper ions to other
proteins. Importantly, the lack of signiWcant conformational
changes to CuBD on copper binding suggests a model in
which copper binding aVects the dimerisation state of APP
leading to reduction in A production. We thus predict that
disruption of APP dimers may be a novel therapeutic
approach to treat Alzheimer’s disease.
Keywords Alzheimer’s disease · Amyloid precursor 
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Introduction
Alzheimer’s disease (AD) is characterised pathologically
by the presence of amyloid plaques, extensive neuronal
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death and shrinkage of the brain. The symptoms of the
disease begin with short-term memory disturbances and
disorientation, and as the disease progresses judgement and
reasoning become impaired and the suVerer dies after
several years of dementia. Currently there is no treatment
for the disease, although acetylcholinesterase inhibitors
have displayed some moderate beneWt in treatment.
There is increasing evidence that the neurotoxic A pep-
tide can compromise neuronal functions and trigger cell
death (Selkoe 2002). The peptide can aggregate into small
soluble oligomers, eventually leading to the amyloid
plaques observed in AD diseased brains. Small soluble
oligomers of A have been shown to cause damage to cul-
tured neurones (Haass and Selkoe 2007). The peptide is
derived from the cleavage of the amyloid precursor protein
(APP) and is the main constituent of the amyloid plaques
(Kang et al. 1987). APP belongs to a larger family of APP-
like proteins (APLPs) and homologues have been identiWed
in a range of higher organisms including worms, insects
and rodents (Coulson et al. 2000). These proteins exhibit
some functional redundancy but only APP cleavage gives
rise to the A peptide. The cleavage occurs during traYck-
ing and maturation through the protein secretory pathway
by membrane-bound proteases. A arises through the
sequential cleavage by the BACE enzyme (Sinha et al. 1999;
Yan et al. 1999) at a site just outside the plasma membrane
and the -secretase protein complex (Haass and Steiner
2002) within the membrane (Fig. 1). An alternative APP
proteolytic pathway exists in which cleavage by -secretase
results in the release of soluble APP. The secreted APP has
been shown to possess growth-promoting activities and can
bind to extracellular matrix components (De Strooper and
Annaert 2000). This major pathway is non-amyloidogenic
since it cleaves close to the middle of the A peptide and
therefore prevents intact A peptide formation.
APP as a signalling molecule
Amyloid precursor protein is a Type-I transmembrane pro-
tein with a large extracellular region that can be subdivided
into several distinct domains (Fig. 1). At the N-terminus is
a cysteine-rich region consisting of the growth factor
domain (GFD), which binds heparin and can stimulate neu-
rite outgrowth (Ohsawa et al. 1997; Rossjohn et al. 1999)
and a copper-binding domain (CuBD) (Barnham et al.
2003). The cysteine-rich region is followed by an acidic-
rich region, a Kunitz-type protease inhibitor (KPI) domain
and an OX2 domain (Tanaka et al. 1988; Tanzi et al. 1988).
The KPI and OX2 domains can be spliced out, to produce
three main variants: APP770 (with 770 amino acid residues),
APP751 and APP695. The latter is the most common isoform
in the brain (Haass et al. 1991). Following these domains is
a glycosylated domain referred to as E2 (Wang and Ha
2004) and an unstructured region immediately preceding
the transmembrane domain. The E2 domain possesses a
RERMS sequence that may contribute to APP’s growth-
promoting properties and it also has a heparin binding site.
The C-terminal cytoplasmic tail is involved in various
cellular functions through interaction with a multitude of
proteins (De Strooper and Annaert 2000).
The function of normal APP remains largely unknown.
There is appreciable evidence that APP acts as a cell
surface receptor. It shares a similar architecture, cellular
orientation and localisation to known (Type-1) cell surface
receptors (Kang et al. 1987; Weidemann et al. 1989;
Schubert et al. 1991). The APP cytoplasmic domain has
been shown to bind to Fe65 protein, a protein related to
oncogenic signal transducers, implicating a role for APP as
a cell surface signalling receptor (Cao and Südhof 2001).
Mouse knockouts of either APP, APLP1, APLP2 or their
binding partner Fe65 cause the same phenotype of cortical
Fig. 1 Domain arrangement of APP highlighting some important
regions of the molecule. Cartoon ribbon pictures of known 3D
structures of domains are shown at the top of the picture. The N-termi-
nal growth factor domain (GFD; PDB id: 1MWP) is followed by
CuBD (PDB ids: 1OWT, 2FKL, 2FJZ and 2FK3), an acidic-rich
region, Kunitz-type protease inhibitor (KPI; PDB id: 1AAP) and OX2
domains that occur in some APP isoforms, a couple of glycosylated
domains (D6a, sometimes called the E2 domain or CAPPD; PDB ids:
1TKN, 1RW6; followed by an unstructured domain we refer to as
D6b), a transmembrane region (TM) and a cytoplasmic tail. The loca-
tion of the A region, a major component of Alzheimer’s disease
plaques, is shown. The sequence of CuBD is shown with the copper
binding ligands and Met170 in large bold type and the cysteines that are
involved in disulWde bridges shown in underlined bold typeEur Biophys J (2008) 37:269–279  271
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dysplasias suggesting the phenotype is caused by decreased
transmission of an APP-dependent signal through the Fe65
protein (Guenette et al. 2006). APP hereditary mutations
that are linked with Alzheimer’s disease, can cause consti-
tutive activation of Go, a member of the heteromeric G pro-
tein family that serve as signal tranducers of cell surface
receptors (Okamoto et al. 1995). An antibody directed
towards the APP N-terminal domain stimulates G protein
and MAP kinase activity (Okamoto et al. 1995). The anti-
body is presumably mimicking the action of a still-to-be-
identiWed physiological ligand. There is evidence that APP
exists in a monomer to dimer equilibrium in the membrane
(Scheuermann et al. 2001; Soba et al. 2005) and the binding
of high molecular weight heparin induces dimerisation
(Gralle et al. 2006). Dimerisation may cause an initiation of
signalling events (Sondag and Combs 2004) and play a role
in modulating APP cleavage as the production of A is
increased when APP is forcibly dimerised (Scheuermann
et al. 2001).
APP as a copper binding molecule
Copper is essential to life but is also toxic and as a result
cells have developed elaborate systems for copper storage
and transport (Bush 2000). The CuBD of APP can strongly
bind Cu(II) (Kd
APP t 10 nM) and reduce it to Cu(I) in vitro
(Hesse et al. 1994; Multhaup et al. 1996). This can lead to
increased copper mediated neurotoxicity in cultured neuro-
nes (White et al. 1999a), presumably through increased oxi-
dative stress or the generation of reactive oxygen species
(Multhaup et al. 1997). APP appears to play a role in cop-
per transport. In particular, a role for APP in copper eZux
has been supported by a series of experiments which dem-
onstrated an increased intracellular accumulation of copper
in neuronal cultures (Bellingham et al. 2004) and in the
brains of APP/APLP2 double knockout mice (White et al.
1999b) whilst transgenic over-expression of APP had the
opposite eVects in cultured neurones and mice (Maynard
et al. 2002; Bellingham et al. 2004). The involvement of
CuBD in copper eZux has been demonstrated in yeast
expressing an APP ectodomain fragment. Mutating the
copper binding residues in CuBD signiWcantly increases
intracellular copper levels compared to yeast expressing a
wild-type fragment (Treiber et al. 2004).
The interaction between copper ions and CuBD can
modulate A production. The treatment of CHO cells over-
expressing APP with extracellular Cu(II) leads to reduced
A production and a shift of the cleavage equilibrium away
from the amyloidgenic pathway (Borchardt et al. 1999).
The eVects are abolished when the copper binding residues
of CuBD are mutated (Borchardt et al. 2000). The possible
beneWcial outcomes of Cu(II) binding to APP have been
suggested in two independent transgenic mouse studies.
The survival of APP23 mice (which overproduce A) was
improved along with reduced A-levels in the brain when
their drinking water was supplemented with Cu(II) ions
(Bayer et al. 2003). Similar eVects were achieved by cross-
ing TgCRND8 mice (that overproduce A) with mice that
have raised brain copper levels due to the expression of a
mutant copper transporter CuATPase7b. These mice had
decreased amyloid plaque and plasma A levels (Phinney
et al. 2003).
A molecular target for the APP:Cu or APLP2:Cu com-
plexes is the proteoglycan molecule glypican-1 (Cappai
et al. 2005). APP and APLP2 can regulate the non-enzy-
matic metabolism of the glypican-1 heparin sulfate side-
chains in a copper-dependent manner in vitro and in vivo.
The APP : Cu complex stimulates glypican-1 autodegrada-
tion in the presence of either Cu(II) and Zn(II) ions,
whereas the Cu(I) form of APP and the Cu(II) and Cu(I)
forms of APLP2 inhibit autodegradation (Cappai et al.
2005).
In addition to copper binding to CuBD, copper is also
known to bind the A peptide fragment of APP, inducing
peptide aggregation and leading to the production of reac-
tive oxygen species via Fenton chemistry (Smith et al.
2007). The interested reader is referred to more in-depth
reviews on this topic found elsewhere in this special issue.
CuBD structure
To understand the interaction of copper with APP at the
molecular level, we initially determined the three-dimen-
sional structure of CuBD (APP residues 124–189) by
nuclear magnetic resonance spectroscopy (NMR) (PDB id:
1OWT; Barnham et al. 2003). This work revealed that the
CuBD structure consists of an -helix (residues 147–159)
packed against a triple-stranded -sheet (residues 133–139,
162–167 and 181–188) (Fig. 2a). A Cys144–Cys174 disulWde
bond connected two loops at one end of the molecule. On
the other end a disulWde bond between Cys133 and Cys187
linked strands 1 and 3 and another between Cys158 and
Cys186 linked the -helix to strand 3. The surface of CuBD
is highly charged with several areas of high negative
(Glu156, Glu160, Glu183, Asp167 and Asp131) and positive
(Lys132, Lys134, Lys161, His147, His151 and Lys155) charge.
CuBD belongs to the class of mixed / proteins, displays
an architecture of a two-layered sandwich, with a topology
that can be classiWed as either - plaits or defensin A-like
(Pearl et al. 2005). Proteins that exhibit the latter topology
include copper transport proteins such as yeast metallo-
chaperone Atx1 (Arnesano et al. 2001), human metallo-
chaperone HAH1 (Anastassopoulou et al. 2004) and the
metal-binding domains of Menkes Protein ATP7A (Banci
et al. 2004, 2005). These proteins contain an additional
-helix and -strand after the  motif of CuBD and272 Eur Biophys J (2008) 37:269–279
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display no sequence similarity to CuBD. Their copper binding
sites are located on the surface, but unlike CuBD, in the
loop joining strand 1 and helix 1, and use two cysteines in
a CXXC motif as copper ligands.
More recently we determined the crystal structure of apo
CuBD from three diVerent crystal forms at high resolution
(Fig. 2a) (PDB ids: 2FKL, 2FJZ, 2FK3; Kong et al. 2007a).
These structures revealed eleven diVerent views of the mol-
ecule due to multiple copies in the asymmetric unit in some
crystal forms. Despite the diVerent crystal lattice forces,
these structures superimpose closely amongst each other
and with the previously determined NMR structure
(Barnham et al. 2003). Major deviations are largely restricted
to loops and are attributable to various crystal packing con-
tacts. Backbone atoms of the copper binding residues
superimpose closely despite being involved in diVerent
types of crystal contacts amongst the crystal forms. The rel-
ative positions of those side-chains are also well conserved,
although His147 is seen to adopt diVerent side-chain orienta-
tions, which may be relevant for copper transport to and
from other proteins (see below).
We have just reported the crystal structure of CuBD in
metal-free form at ultra-high resolution (0.85 Å) (PDB id:
2FMA; Kong et al. 2007b). The structure shows that the
copper binding residues of CuBD (see below) are rather
rigid but Met170, thought to be the electron source for Cu(II)
reduction, adopts two diVerent side-chain conformations. In
one, the thioether is about 7 Å from the copper binding site
and points away from the other copper binding residues. In
the second conformation, the thioether group is closer to
the copper binding site (6 Å) and points towards the copper
ion, although Met170 itself is still buried from the surface.
The Xexibility of the Met170 side-chain may be important in
facilitating copper ion binding or the reduction of Cu(II) to
Cu(I) after Cu(II) is bound to the CuBD (White et al. 2002;
Barnham et al. 2003).
Copper binding to CuBD
The conformation of Cu(II)-binding residues in CuBD
could not be visualised by NMR as the paramagnetism of
Cu(II) caused severe peak broadening arising from atoms in
close proximity to the metal ion and addition of metals such
as copper and zinc induced protein aggregation in solution
(Barnham et al. 2003). However, this paramagnetic eVect
implicated His147, His151, Tyr168 and Met170 in Cu(II) bind-
ing. Copper ions could not be introduced to CuBD either by
co-crystallisation nor by soaking preformed crystals at high
concentrations of copper without causing crystal shattering,
likely due to numerous copper binding sites on the surface
of the protein. However, careful manipulation of the soak-
ing conditions led to crystals in which the high aYnity cop-
per binding site was occupied without crystal destruction.
Fig. 2 Three-dimensional structure of CuBD (Kong et al. 2007a). a
Ribbon picture of apo CuBD (PDB ids: 2FKL, 2FJZ and 2FK3) high-
lighting some of the side-chains that contribute to the copper binding
site. b The Cu(II) coordination geometry in CuBD (PDB id: 2FK1) and
comparison of the copper binding residues in the Cu(II)-bound and apo
structures. The Cu(II)-bound structure is displayed in standard atomic
colouring and the apo structure is in grey. The Cu(II) ion is indicated
by the arrow, while ‘eq’ and ‘ax’ denote the equatorial and axial water
molecules, respectively. C The Cu(I) coordination geometry in CuBD
(PDB id: 2FK2) and a comparison of the copper binding site in the
Cu(II)-bound and Cu(I)-bound CuBD structures. The Cu(II)- and
Cu(I)-bound structures are shown in standard atomic colouring and in
grey, respectivelyEur Biophys J (2008) 37:269–279  273
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Our structure derived from such crystals revealed that the
two histidines (His147, His151) and the tyrosine residue
(Tyr168) participate in Cu(II) binding but not the methionine
residue. In addition, two water ligands were identiWed: an
axial water and an ‘equatorial’ water molecule located
»1.5 Å above the plane of the other ligands (Fig. 2b) (PDB
id: 2FK1; Kong et al. 2007a). The arrangement of ligands
about the metal centre is typical of the square pyramidal
geometry normally adopted by Wve coordinate Cu(II) and
can be classiWed as a Type 2 non-blue Cu(II) centre in
which the metal is normally bound by two or three nitrogen
atoms and oxygen atoms (http://metallo.scripps.edu/
PROMISE/CUMAIN.html). The copper binding geometry
is consistent with observations suggesting that APP is capa-
ble of reducing Cu(II) to Cu(I) (Multhaup et al. 1996) as
Type 2 sites are often associated with redox-driven cataly-
sis (Messerschmidt et al. 2001). A similar Type 2 site has
been described in nitrosocyanin which is also open to
solvent and involves a water ligand (Arciero et al. 2002).
The Cu(II) coordination geometry was further conWrmed
by electron paramagnetic resonance spectroscopy and
extended X-ray absorption Wne structure spectroscopy of
Cu(II)-bound CuBD in solution (Kong et al. 2007a).
We also determined the crystal structure of the Cu(I)
form of the protein through the use of a reductant on the
Cu(II)-bound CuBD crystals (PDB id: 2FK2; Kong et al.
2007a). The Cu(I) binding geometry is almost identical to
that of Cu(II) in CuBD (see above) with such small diVer-
ences between oxidation states having been noted previ-
ously for other copper proteins (Gray et al. 2000).The only
signiWcant diVerence is the absence of the axial water
ligand (Fig. 2c). Similar losses of a water ligand upon
Cu(II) reduction have been observed in a couple of other
copper redox proteins (Murphy et al. 1997; Basumallick
et al. 2005). Normally four coordinate Cu(I) adopts a tetra-
hedral geometry and binds soft ligands (Casella and
Gullotti  1993) rather than the distorted square planar
arrangement and oxygen ligands seen for CuBD. Thus, the
site appears unfavourable for Cu(I) suggesting the Cu(I)-
bound state may not be stable, possibly facilitating the
transfer of metal to other proteins following CuBD-medi-
ated reduction of Cu(II).
The NMR Cu(II) titration experiments led to evidence of
Met170 oxidation and peak broadening of its proton reso-
nances suggesting that it was in the neighbourhood of the
metal ion (Barnham et al. 2003). However, in the crystal
structures we found that sulfur atom of Met170 is 7 Å from
either the Cu(II) or Cu(I) ion (Fig. 2b,c) (Kong et al. 2007a,
b). We propose that Met170 may play an important role as
an electron donor to Cu(II) either through rapid conforma-
tional changes which would bring the sulfur atom in close
contact with the metal ion, or through an electron transfer
pathway which relays the electron from Met170 to Cu(II)
through the copper binding residues. The proximity of
Met170 and Tyr168 in CuBD provides a plausible electron
transfer pathway; reminiscent of a similar mechanism pro-
posed for A peptide-induced Cu(II) reduction where a
methionine residue has been suggested to provide the elec-
tron for Cu(II) reduction through a tyrosine ligand (Curtain
et al. 2001; Barnham et al. 2004).
The surface location of the copper site in CuBD may
facilitate the transfer of metal ions to and from other cop-
per-binding proteins. This is, in a sense, similar to the case
of the metal-binding domains of the human Menkes protein
(ATP7a), where Cu(I) also binds in an exposed environ-
ment after it is delivered from the chaperone HAH1
although the ligands involved are exclusively cysteines
(Banci et al. 2005). In the case of the yeast chaperone pro-
tein Atx1, its interaction with its downstream target Ccc2
ATPase (Ccc2a) involves bringing the Cu(I) ion from a
more shielded environment to the surface where the cyste-
ine ligands of Ccc2a would be able to chelate the Cu(I)
from Atx1. The Atx1-Ccc2a interaction, although aided by
other forces, is absolutely dependent on Cu(I) binding
(Banci et al. 2006). We can similarly envisage the interac-
tion of CuBD and its partners being driven by the presence
of copper ions. The water ligands in CuBD could suggest
where an endogenous ligand or binding partner of CuBD
may dock by displacing these waters (Prigge et al. 2004).
The putative ligand could come from a number of sources:
(a) another ligand of the CuBD, (b) from an adjacent
domain within the same protein molecule, (c) from another
APP molecule to form an oligomer, or (d) a binding partner
of APP, such as proteins that transport copper ions to or
from APP. The third possibility would be consistent with
the observation that CuBD may form part of the APP
dimerisation interface (Scheuermann et al. 2001; Soba et al.
2005) and the positions of the water molecules may repre-
sent where the dimer interactions occur. The crystal pack-
ing interactions seen in some of the CuBD crystal forms
suggest a propensity of the copper binding residues to take
part in protein–protein interactions. However, we have not
observed speciWc CuBD oligomerisation induced by Cu(II)
(unpublished results).
Modelling CuBDs from other species
One of the consequences of Cu(II) binding to APP is
thought to be neuronal toxicity which has been demon-
strated so far in cultured neurones. The hypothesised role
of CuBD in neuronal toxicity is that the bound Cu(II) is
reduced to Cu(I), which can then lead to lipoprotein per-
oxidation and free radicals that damage the cell (White
et al. 2002). CuBD is one of the best conserved domains
within the APP superfamily (Fig. 3). Surprisingly, the
eVect of copper binding varies between the orthologues274 Eur Biophys J (2008) 37:269–279
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and paralogues. For example, it has been shown that the
presence of Cu(II) salts in primary murine neuronal cul-
tures causes greater cell death in wild-type neurones com-
pared to APP¡/¡ neurones whereas there is no diVerence
between wild-type and APLP2¡/¡ neurones (White et al.
1999a). Lipoprotein peroxidation is enhanced by Cu(II)-
treated ectodomain of human APP and APLP2, whereas
neither the non-metallated forms of those proteins nor
Cu(II)-metallated human APLP1 show increased peroxi-
dation above background (White et al. 2002). Cu(II)-
bound CuBD of human APP appears suYcient in the
generation of Cu(I) and causing neuronal cell death
(White et al. 2002).
The behaviour of peptides derived from CuBDs of vari-
ous APP homologues suggests that the toxicity may depend
on the presence of the copper binding histidine residues.
The replacement of one, and both of those histidines results
in an inert and protective eVect, respectively, when the pep-
tides are added to cultured neurones incubated with lipo-
proteins. The peptides studied were derived from human
APLP1 (one histidine replaced), Caenorhabditis elegans
homologue APL-1 (two histidines replaced) and Drosophila
melanogaster homologue APPL (two histidines replaced).
However, these fragments do not cover the position
corresponding to the copper binding residue Tyr168 and
do not preserve the native disulWde bonds. Hence the
structure, binding behaviour and Cu(II) reduction mecha-
nism of the peptides are very likely to be diVerent in intact
CuBD.
We have produced three-dimensional atomic models of
selected CuBDs from various organisms using homology
modelling based on the sequence alignments shown in
Fig. 3. The sequence alignment shows that the copper bind-
ing residues of human APP are not conserved in the APLP-
1 family, C. elegans homologue APL-1 or D. melanogaster
homologue APPL (Fig. 3). The replacement of the copper
binding residues in human APLP-1 (Fig. 4b), C. elegans
APL-1 (Fig. 4c) and D. melanogaster APPL (Fig. 4d) likely
abolishes copper binding since residues are eliminated that
are likely to be involved in copper coordination and the dis-
tance between the putative Cu(II) ion binding site to the
surrounding residues increases (Fig. 4).
Those APP homologues where the CuBD models are
predicted to lack the copper binding site will not be able to
bind Cu(II) and thus reduce it to the more toxic Cu(I). This
would explain why human APLP-1 is not able to oxidise
lipoproteins and cause neuronal death (White et al. 2002). It
is also consistent with the protective eVect of D. melano-
gaster APPL and C. elegans APL-1 CuBD peptides against
lipoprotein peroxidation by Cu(II) ions. If the hypothesis
on Cu(II)-induced toxicity holds, the result of modelling
would support the role of His147, His151 and Tyr168 of
human APP CuBD in copper binding.
The copper binding site of human APLP-2 CuBD is pre-
dicted to be very similar to human APP CuBD based on
comparison of primary structures (Fig. 3) and the similarity
of the APLP-2 CuBD homology model with the crystal
structure (Fig. 4a). In view of the high similarity of the
Cu(II)-bound, Cu(I)-bound and apo structures of human
APP CuBD (see above), it is expected that the Cu(II)-
bound and Cu(I)-bound structures of human APLP-2 CuBD
would be very similar as well. The copper binding residues
His147, His151 and Tyr168, are also conserved in APLP-2s in
other organisms, but the toxicity mediated by APLP-2s
appears to be lower than APPs. For example, Cu(II)-bound
human APP is more eVective than Cu(II)-bound human
APLP-2 in oxidising lipoproteins and causing cell death
(White et al. 2002). Wild-type murine hippocampal neuro-
nes suVer greater cell death compared to mouse APP¡/¡
counterparts while mouse APLP-2¡/¡ oVers no protection
(White et al. 1999a). The crystal structure of human APP
CuBD and the model of human APLP-2 CuBD do not pro-
vide an obvious explanation for the diVerent toxicity eVects
mediated by these two APP homologues.
Fig. 3 A sequence alignment of CuBD from selected members of
the APP superfamily. The preWxes h, r, m, d and c denote human,
rat, mouse, Drosophila melanogaster and Caenorhabditis elegans,
respectively. The N-terminal and C-terminal numbering of each CuBD
are listed. Conserved residues are indicated by asterisks and coloured
in aqua, colons indicate positions with very similar amino acid resi-
dues while dots indicate positions with some similarity. The copper
binding residues of human APP CuBD and their equivalents in other
homologues are coloured in orangeEur Biophys J (2008) 37:269–279  275
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Modelling CuBD interactions with GFD
The N-terminal GFD is immediately upstream of CuBD
(Fig. 1) and together they constitute the cysteine-rich
region of the molecule. To determine if these two domains
likely interact we used the GRAMM program (Vasker and
AXalo 1994; Vasker 1996) to dock CuBD to the crystal
structure of GFD (PDB id: 1MWP; Rossjohn et al. 1999).
Visual inspection indicated that the most plausible domain
pair structure brought the C-terminus of GFD and the
N-terminus of CuBD in close proximity while the arrange-
ment of the domain interface was suggestive of a continua-
tion of the -sheet from domain 1 into the -sheet of
domain 2 (Fig. 5). The total surface area buried in forming
the interface is »200 Å2. The residues forming the interface
are primarily hydrophobic, including Val86, Leu118, Val119
and Gly120 from GFD and Ala126, Leu127, Leu128, Val129 and
Pro130 of CuBD with the ends of this hydrophobic region
Xanked by polar and charged residues that are exposed to
solvent. In total there are nine potential hydrogen bonds
and 28 van der Waals interactions in the domain interface.
Both the heparin binding site of GFD and the copper bind-
ing site of CuBD, are exposed in the model at opposite ends
of the cysteine rich region, separated by »50 Å.
We have determined the crystal structure of a longer
length fragment of CuBD124–189 to 2.5 Å resolution (Kong
et al.  2007a). This crystal from was found to have two
CuBD molecules in the asymmetric unit. An interesting
feature of this structure is that the two molecules interact
head-to-head via new -strand (0) involving residues 127–
129 of one molecule hydrogen bonding onto strand 2 of a
neighbouring molecule to form an extended -sheet
(Fig. 6). The interaction buries about 1,550 Å2 of surface
area between the molecules. However, there are a few con-
tacts between the two chains. The new strand 0 of chain B
provides some of those interactions through hydrogen
Fig. 4 A comparison of the human APP CuBD copper binding site to
the equivalent site in orthologues and paralogues. a Human APLP-2, b
human APLP-1, c D. melanogaster APPL and d C. elegans APL-1.
The human APP residues are shown in green sticks whereas the homol-
ogy models are in ball-and-stick with the standard atomic colouring276 Eur Biophys J (2008) 37:269–279
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bonds from the backbone amides of Ala126 (B) and Leu127
(B) to the backbone carbonyl of Met170 (A), and that from
the backbone carbonyl of Tyr168 (A) to backbone amide of
Val129 (B). There are van der Waals contacts between the
rings of His147 (A) and Phe135 (B), between the backbone of
Gly175 (A) and side-chain of Leu171 (B), between the side-
chains of Asp177 (A) and His137 (B), and a hydrogen bond
between the backbone amide of Asp177 (A) and carboxylate
group of Glu183 (B). Strand 0 is also within van der Waals
distance of the copper binding site of the latter molecule.
However, it is unlikely that the dimer seen in this crystal
form has a signiWcant existence in solution because there
is no evidence of dimerisation of CuBD124–189 in the
NMR experiment (Barnham et al. 2003). Nevertheless, the
structure shows that N-terminal residues 124–132 of CuBD
have an inherent propensity to form a -strand and thus
lends support to the suggestion discussed above that this
region of CuBD could be induced to form a strand leading
to the extended -sheet with GFD in intact APP (Fig. 5).
In a recent collaboration an ab initio reconstruction of a
molecular model of the complete extracellular region of
APP (sAPP) was presented based on data from high-resolu-
tion solution X-ray scattering (SAXS) data together with
the  Wtting of domains from published crystal structures
(Gralle et al. 2006). In this model the N-terminal growth-
factor domain and CuBD would lie at a distance of »100 Å
from the membrane. The results from SAXS, analytical
ultracentrifugation (AUC) and size-exclusion chromatogra-
phy (SEC) analysis indicated that sAPP is monomeric in
solution. On the other hand, SEC, Xuorescence, AUC and
SAXS measurements showed that sAPP forms a 2:1 com-
plex with heparin. A model for the sAPP:heparin complex
was also derived from the SAXS data.
Copper binding to APP: implications for signalling
Our structures do not directly explain how copper binding
leads to decreasing A production since we see no evidence
of signiWcant conformational changes in the structure of
CuBD upon metal binding or reduction. However, it must
be mediated by some sort of signalling mechanism, for
example, modulation of proteins that cleave APP (Angeletti
et al. 2005), a change in conformation of APP, recruitment
of other proteins or a change in the oligomerisation state of
the APP. APP can associate with Go as a G-protein coupled
receptor (Brouillet et al. 1999) and signalling can be initi-
ated upon binding of an antibody, 22C11, that binds to the
GFD and is thought to act as a ligand mimetic (Okamoto
et al. 1995). Scheuermann et al. (2001) were able to isolate
endogenous membrane-bound APP as dimers and showed
that A production increased when APP was cross-linked
to form dimers. However, it cannot be excluded that the
eVect on A production could have been as a consequence
of modifying APP near its -secretase cleavage site. Puta-
tive dimerisation domains have been proposed. Wang and
Ha (2004) suggested the E2 domain (Fig. 1) as a candidate.
On the other hand, Scheuermann et al. (2001) demonstrated
that a fragment encompassing the GFD, CuBD and the
acidic-rich region existed in dimeric form by gel Wltration,
while Soba et al. (2005) showed that the GFD and CuBD
Fig. 5 Model of the APP growth factor domain docked onto CuBD.
Note that an extra -strand (coloured yellow), suggested by the model-
ling, has been inserted between the two domains to form an extended
sheet
Fig. 6 A ribbon diagram of CuBD124–189. Chains A and B are coloured
in grey and green, respectively. Strand 0 of chain B is highlighted in
red. The side-chains of the copper binding residues and Met170 are
shown as blue sticksEur Biophys J (2008) 37:269–279  277
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might be a major site of dimerisation of APP in the cellular
context. If the CuBD does contribute to APP dimerisation
in the absence of Cu ions, we propose that the eVect of
Cu(II) in lowering A production may perhaps be elicited
through either a shift of monomer-dimer equilibrium to
favour monomers or a re-orientation of the APP dimers to a
form that disfavours A production (Fig. 7). If the copper
site is exposed in the monomeric or re-orientated dimer
form, it could also aid the interaction of APP with other
copper binding proteins in the transfer of copper ions. The
copper binding pocket, perhaps together with other parts
of CuBD or APP, will provide a site for the docking
of interacting partners. Based on this hypothesis, new
approaches to Alzheimer’s therapeutics could be devised,
as compounds that can disrupt the formation or organisation
of pre-formed APP dimers may be beneWcial in reducing
A production from APP.
Concluding remarks
Copper binding to APP can yield paradoxical outcomes. On
the one hand copper binding to the CuBD of APP results in
A depletion whereas copper binding to the A peptide
generates toxic species. From a therapeutic point-of-view
these observations suggest that a molecule that mimics the
eVect of copper binding on CuBD could be of signiWcant
clinical beneWt.
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